Arrakis - Arrakis Therapeutics
Arrakis set out on a clear mission to open new territories of medicine by creating a pioneering class of genetic medicines: RNA-targeted small molecules (rSMs). Today, our progress has changed the landscape and defined new rules for targeting …
News Releases - Arrakis Therapeutics
Feb 8, 2022 · Arrakis Therapeutics Unveils Data for its Lead, Rationally Designed, RNA-Targeted Small Molecule (rSM) Drug Program Demonstrating Disease-Modifying Binding to RNA to Treat Myotonic Dystrophy
Arrakis to shift away from pursuit of RNA-intercepting cancer …
Dec 4, 2024 · Arrakis was formed with the idea of drugging RNA to fight cancer. Despite some promising data, CEO Michael Gilman is shifting targets.
Arrakis Therapeutics Unveils Data for its Lead, Rationally Designed ...
Dec 4, 2024 · These preclinical data demonstrate Arrakis’s leading-edge capability to rationally design a disease-modifying RNA-targeted small molecule, using its pioneering and comprehensive drug discovery...
Arrakis Therapeutics lays off 20% of its workforce - The Business …
Mar 4, 2024 · Arrakis Therapeutics parted ways with about 20% of its workforce last week. CEO Michael Gilman confirmed the layoffs to the Business Journal on Monday, writing in an emailed statement that the...
Amgen and Arrakis Therapeutics Announce Multi-Target …
THOUSAND OAKS, Calif. and WALTHAM, Mass., Jan. 11, 2022 – Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a range of difficult-to-drug targets in multiple therapeutic areas.
AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI …
Jan 11, 2022 · Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas.
Arrakis overcomes industry 'skepticism,' names lead program
Dec 4, 2024 · CEO Michael Gilman said Arrakis faced an “unbelievable amount of skepticism” when it got started around 2017. In an interview with the Business Journal, Gilman explains how the company charted a...
Amid a pandemic, Roche bets $190M on Arrakis and drugging RNA
Apr 8, 2020 · Arrakis now has a pipeline that includes potential drugs for cancer, neurological diseases, rare disorders, and dyslipidemia. The Roche deal is the company's first, but it marks one of the largest bets on RNA-targeting small molecule …
Arrakis’ RNA-targeted oral therapies showing promise for DM1
Dec 5, 2024 · Arrakis is working on developing oral small molecules that specifically bind to the CUG repeats in DMPK RNA, preventing the molecules from clumping. That’s expected to free important splicing factors that are needed for normal protein production, thereby easing myotonia and other symptoms.